Medical News

Sustained SBP Control cuts down the Risk of Stroke, HF and CVD in Hypertensives, States ALLHAT Analysis

Sustained systolic blood pressure (SBP) control may be beneficial for preventing stroke, heart failure (HF), and cardiovascular disease (CVD)...

20 Mar, 2019

Email this page
Effect of Switching to Azilsartan from Fixed-Dose Combination for Treating Hypertension

A recent study demonstrated the efficacy of 40 mg azilsartan in lowering blood pressure (BP) to be similar to that of a fixed dose combination of...

11 Mar, 2019

Email this page
Decrease in Adiposity during Adolescence has Beneficial Impact on Blood Pressure

A recent novel study suggested that decreases in adiposity (as measured by changes in body mass index and waist circumference ) during early...

06 Mar, 2019

Email this page
In-Hospital Mortality and Bleeding Complications after PCI, More Frequent in Older Patients Especially Nonagenarians

Old patients, including few selected nonagenarians, with or without acute coronary syndrome (ACS) are frequently treated with percutaneous coronary...

04 Mar, 2019

Email this page

Key Trials

Six Months vs. Twelve Months of DAPT in Event-Free STEMI Patients after Primary PCI with Second Generation DES

The study demonstrated six months of DAPT to be non-superior to 12 months of DAPT in STEMI patients who remain event free after primary PCI with...

TRANSITION Study: Feasible and Safe to Initiate Sacubitril/Valsartan Pre-discharge in Acute HFrEF

The TRANSITION study indicates early initiation of sacubitril/valsartan pre-discharge in acute HFrEF patients is a feasible and safe option.

Impact of Sacubitril-Valsartan Treatment on Patients Hospitalized for Acute Decompensated HF

The PIONEER-HF trial ascertains the impact of sacubitril-valsartan therapy in hemodynamically stable patients hospitalized for acute decompensated...

Sacubitril/Valsartan Improves Physical and Social Activity Limitations in HFrEF Patients

Treatment with sacubitril/valsartan improves physical and social limitations in HFrEF patients in addition to the CV benefits that it provides.

Slide Library

Medical Management Strategy of CTEPH: Role of Riociguat

Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...

Email this page
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...

Email this page
Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

Email this page

Our Publications

Gutron (Midodrine hydrochloride) Monograph

Orthostatic Hypotension is common in elderly (>70 years of age) and can also occur secondary to neuropathy like in diabetes or central lesions...

Azmarda (Sacubitril/Valsartan) FAQs

This booklet on frequently asked questions on sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) provides...

Retefast (Reteplase) Datasheet

This datasheet provides an overview on the pharmacology, clinical efficacy, safety, indications and dosage of reteplase.

Pulmonary Hypertension – An Update

This article summarises the definition, classification, pathogenesis, assessment, prognosis, diagnosis and treatment for PH.


What percent of your patients who need oral anticoagulation, receive warfarin?
31% (5 votes)
13% (2 votes)
6% (1 vote)
13% (2 votes)
31% (5 votes)
Almost all
6% (1 vote)
Total votes: 16